Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31583128 | 0.87 | MAPT (0.63) | KDM4ELTA4HALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL4232561 | 0.87 | HTR2A (0.64) | KDM4ELTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL3156422 | 0.87 | KDM4E (0.73) | KDM4EALDH1A1SMN1; SMN2HRH3KMT2A | |
| SCHEMBL1414283 | 0.87 | ALDH1A1 (0.67) | KDM4ELTA4HALDH1A1NPC1RAB9A | |
| SCHEMBL27541561 | 0.86 | HTR2A (0.63) | KDM4ELTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL1414196 | 0.86 | KDM4E (0.61) | KDM4ELTA4HALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL5787227 | 0.83 | KCNJ1 (0.68) | ALDH1A1SMN1; SMN2HRH3KMT2AKCNH2 | |
| SCHEMBL12156559 | 0.82 | KCNH2 (0.76) | LTA4HALDH1A1HRH3NPC1RAB9A | |
| Fumaric Acid SCHEMBL15567023 | 0.81 | LTA4H (0.53) | KDM4ELTA4HALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL8491424 | 0.81 | HTR2A (0.57) | LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212318-B1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1212318-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | KDM4E 221/4885LTA4H 3246/4885ALDH1A1 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.